Table 2.
HR values of OS and DFS of NSCLC subgroups
| Outcome | Studies (n) | Patients | HR | 95%CI | P value | Model | H, I2, P value | |
|---|---|---|---|---|---|---|---|---|
| OS | All study | 28 | 4534 | 1.58 | 1.33-1.87 | 0.000 | Random | 100.02,74.0 %,0.000 |
| Asian | 14 | 2729 | 1.97 | 1.43-2.71 | 0.000 | Random | 72.62,82.1 %,0.000 | |
| Non-Asian | 14 | 2278 | 1.37 | 1.15-1.64 | 0.013 | Random | 22.99,74.0 %,0.000 | |
| Stage I | 8 | 1144 | 1.85 | 1.27-2.69 | 0.001 | Random | 32.90,78.7 %,0.000 | |
| Stage I-II | 8 | 1166 | 1.72 | 1.20-2.46 | 0.003 | Random | 29.43,76.2 %,0.000 | |
| Stage I-III | 7 | 1038 | 1.60 | 1.21-2.12 | 0.001 | Fixed | 9.44, 36.5 %,0.150 | |
| Stage III-IV | 1 | 58 | 1.31 | 0.68-2.53 | 0.42 | Fixed | - | |
| ADC | 10 | 1327 | 2.21 | 1.38-3.50 | 0.000 | Random | 64.38,86.0 %,0.000 | |
| Asian | 6 | 666 | 3.01 | 1.96-4.02 | 0.000 | Random | 8.70,42.5 %,0.122 | |
| Non-Asian | 4 | 661 | 1.31 | 0.74-2.33 | 0.359 | Random | 18.38,83.7 %,0.000 | |
| Stage I-II | 6 | 446 | 3.30 | 1.37-7.96 | 0.008 | Random | 45.94,89.1 %,0.000 | |
| Stage I-III/IV | 4 | 881 | 1.51 | 0.92-2.47 | 0.102 | Random | 7.75,761.3 %,0.051 | |
| Non-ADC | 2 | 184 | 1.88 | 0.88-4.01 | 0.105 | Fixed | - | |
| DFS | All study | 8 | 1326 | 2.21 | 1.43-3.43 | 0.000 | Random | 28.35,75.3 %,0.000 |
| Asian | 5 | 591 | 2.78 | 1.78-4.34 | 0.000 | Random | 4.67,14.4 %,0.323 | |
| Non-Asian | 3 | 735 | 1.83 | 1.09-3.06 | 0.022 | Random | 48.95,77.7 %,0.01 | |
| Stage I | 3 | 293 | 4.31 | 2.37-7.84 | 0.000 | Fixed | 0.79,0.0 %,0.672 | |
| Stage I-II | 2 | 265 | 1.51 | 1.02-2.23 | 0.038 | Fixed | 0.48,0.0 %,0.486 | |
| Stage I-III/IV | 3 | 783 | 2.02 | 0.97-4.20 | 0.06 | Random | 11.69, 82.9 %, 0.0.06 |
Abbreviation: ADC adenocarcinoma, CI confidence interval, DFS disease-free survival, Fixed, Fixed, Inverse Variance model, H Heterogeneity, HR hazard ratio, I2 I-squared, OS overall survival, Random, Random, I-V heterogeneity model